The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Debbane Raymond since 2019.
This trader's CIK number is 1053890.
At the time of last reporting, Debbane Raymond was the Director of Lexicon Pharmaceuticals, Inc.. (stock ticker symbol LXRX).
Also see all insider trading activities at Lexicon Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | GLYC | 0 | $0 | 2,271,499 | $488,679 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | LXRX | 536,994 | $705,710 | 0 | $0 | 0 | $0 |
| 2025 | LXRX | 0 | $0 | 0 | $0 | 36,810 | $0 |
| 2024 | LXRX | 0 | $0 | 0 | $0 | 8,032 | $0 |
| 2023 | LXRX | 1,000,000 | $1,103,993 | 0 | $0 | 9,302 | $0 |
| 2022 | LXRX | 1,965,200 | $4,913,000 | 0 | $0 | 4,024 | $0 |
| 2021 | LXRX | 0 | $0 | 0 | $0 | 10,638 | $0 |
| 2020 | LXRX | 0 | $0 | 0 | $0 | 3,466 | $0 |
| 2019 | LXRX | 300,515 | $744,627 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | SRRK | 0 | $0 | 2,009,433 | $82,746,684 | 0 | $0 |
1. Crescent Biopharma, Inc. (GLYC)
2. Lexicon Pharmaceuticals, Inc. (LXRX)
3. Scholar Rock Holding Corp (SRRK)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-08-07 | GLYC | Sale | 61,488 | .18 | 11,190 |
| 2024-08-08 | GLYC | Sale | 260,873 | .19 | 50,087 |
| 2024-08-05 | GLYC | Sale | 164,523 | .19 | 30,930 |
| 2024-08-06 | GLYC | Sale | 55,732 | .18 | 10,198 |
| 2024-08-01 | GLYC | Sale | 63,564 | .22 | 13,729 |
| 2024-08-02 | GLYC | Sale | 286,200 | .20 | 57,240 |
| 2024-07-26 | GLYC | Sale | 258,335 | .24 | 62,517 |
| 2024-07-29 | GLYC | Sale | 363,949 | .23 | 85,528 |
| 2024-07-30 | GLYC | Sale | 756,835 | .22 | 167,260 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-02-18 | LXRX | Buy | 133,688 | 1.32 | 176,468 |
| 2026-02-13 | LXRX | Buy | 57,952 | 1.31 | 75,859 |
| 2026-02-17 | LXRX | Buy | 76,857 | 1.31 | 100,528 |
| 2026-02-18 | LXRX | Buy | 133,688 | 1.32 | 176,468 |
| 2026-02-13 | LXRX | Buy | 57,952 | 1.31 | 75,859 |
| 2026-02-17 | LXRX | Buy | 76,857 | 1.31 | 100,528 |
| 2025-05-13 | LXRX | Option Ex | 36,810 | .00 | 0 |
| 2024-04-28 | LXRX | Option Ex | 8,032 | .00 | 0 |
| 2023-10-11 | LXRX | Buy | 342,874 | 1.08 | 370,646 |
| 2023-10-12 | LXRX | Buy | 148,820 | 1.03 | 153,879 |
| 2023-10-10 | LXRX | Buy | 508,306 | 1.14 | 579,468 |
| 2023-05-21 | LXRX | Option Ex | 9,302 | .00 | 0 |
| 2022-08-01 | LXRX | Buy | 982,600 | 2.50 | 2,456,500 |
| 2022-08-01 | LXRX | Buy | 982,600 | 2.50 | 2,456,500 |
| 2022-04-30 | LXRX | Option Ex | 4,024 | .00 | 0 |
| 2021-04-24 | LXRX | Option Ex | 10,638 | .00 | 0 |
| 2020-04-26 | LXRX | Option Ex | 3,466 | .00 | 0 |
| 2019-09-13 | LXRX | Buy | 197,473 | 2.37 | 468,405 |
| 2019-09-13 | LXRX | Buy | 9,269 | 2.46 | 22,848 |
| 2019-09-16 | LXRX | Buy | 93,773 | 2.70 | 253,374 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-12-10 | SRRK | Sale | 1,600,000 | 41.65 | 66,640,000 |
| 2024-11-25 | SRRK | Sale | 409,433 | 39.34 | 16,106,684 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Debbane Raymond (Director of Lexicon Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.